Arimura Kosei, Arima Naomichi, Ohtsubo Hideo, Matsushita Kakushi, Kukita Toshimasa, Ayukawa Tomoko, Kuroki Tomoaki, Tei Chuwa
Department of Hematology and Immunology, Kagoshima University Hospital, Kagoshima, Japan.
Acta Haematol. 2004;112(4):217-8. doi: 10.1159/000081276.
Interferon (IFN)-alpha is a leukocyte-derived cytokine and is used to treat several hematopoietic malignancies. The most common adverse effects of IFN-alpha are flu-like symptoms and usually insignificant. However, adverse effects due to autoimmune mechanisms are often hazardous and irreversible, although their frequency is low. In the present report, we describe a 55-year-old female with chronic myelogenous leukemia who developed severe autoimmune thrombocytopenia during IFN-alpha therapy. The lowest platelet count was 6 x 10(9)/l with severe hemorrhagic tendency. The present report strongly suggests the clinical importance of autoimmune thrombocytopenia as an adverse effect of IFN-alpha.
干扰素（IFN）-α是一种源自白细胞的细胞因子，用于治疗多种血液系统恶性肿瘤。IFN-α最常见的不良反应是类流感症状，通常不严重。然而，尽管自身免疫机制导致的不良反应发生率较低，但往往具有危险性且不可逆转。在本报告中，我们描述了一名55岁的慢性粒细胞白血病女性患者，她在接受IFN-α治疗期间发生了严重的自身免疫性血小板减少症。最低血小板计数为6×10⁹/L，伴有严重的出血倾向。本报告强烈提示自身免疫性血小板减少症作为IFN-α不良反应的临床重要性。
